ORIC — Oric Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1796280 ·
Last close
$8.54
Market Cap
$884.04M
52W High
$14.05
52W Low
$7.23
ADV30
1,298,176
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -39,619,000 | -35,767,000 | 436,762,000 | 56,396,000 | 21,205,000 |
| Dec 2025 | 0 | — | -34,551,000 | -30,505,000 | 408,890,000 | 45,669,000 | 24,528,000 |
| Sep 2025 | 0 | — | -36,671,000 | -32,587,000 | 431,192,000 | 49,668,000 | 24,273,000 |
| Jun 2025 | 0 | — | -39,064,000 | -36,355,000 | 346,857,000 | 75,864,000 | 22,862,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-110,875,000
Investing CF
$-188,456,000
Financing CF
$306,393,000
CapEx
$-327,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-728,009,000
Inventory
—
Receivables
—
ST Investments
$225,536,000
EBIT TTM
$-149,905,000
Pretax Income TTM
$-135,214,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -143,004,000 | -129,468,000 | 408,890,000 | 24,528,000 | — | -110,970,000 |
| Dec 2024 | 0 | -142,895,000 | -127,847,000 | 274,142,000 | 31,020,000 | — | -112,662,000 |
| Dec 2023 | 0 | -110,780,000 | -100,697,000 | 252,007,000 | 27,919,000 | — | -85,688,000 |
| Dec 2022 | 0 | -86,767,000 | -89,122,000 | 247,178,000 | 24,827,000 | — | -75,143,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | $885.29M | $11.10 | — |
| JANX | Janux Therapeutics, Inc. | $878.17M | $14.40 | — |
| ANNX | Annexon, Inc. | $904.41M | $5.52 | — |
| XNCR | Xencor Inc | $862.27M | $11.63 | — |
| SDGR | Schrodinger, Inc. | $862.07M | $13.15 | — |
News headlines (Yahoo Finance, 1h cache)
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
2026-05-17 13:23 · Yahoo
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
2026-05-04 20:05 · Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 20:30 · Yahoo
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Researc
2026-04-17 20:05 · Yahoo
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
2026-04-06 09:08 · Yahoo
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
2026-04-02 12:20 · Yahoo
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3
2026-04-02 08:13 · Yahoo
Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges
2026-04-01 20:16 · Yahoo
Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened
2026-04-01 13:16 · Yahoo
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial
2026-03-31 23:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.